Ipsen Biopharmaceuticals

Ipsen Biopharmaceuticals

BioNJ Member Type: Core

Ipsen (Euronext : IPN ; ADR : IPSEY) is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® (outside the US) and hemophilia (through a partnership). Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees. For more information on Ipsen, visit www.ipsen.com.


106 Allen Road
Basking Ridge, NJ 07920